Working Together to Understand, Protect and Restore Vision
Using a stem cell-derived therapeutic developed over more than a decade in Dr. David Gamm’s lab at UW–Madison, BlueRock Therapeutics has treated the first patient in a new Phase 1/2a clinical trial aimed at a group of inherited retinal disorders (including RP and cone-rod dystrophy). The initiative is the result of a strategic research alliance formed in …
We’re pleased that Chancellor Mnookin has chosen to highlight research from MERI Director David Gamm’s lab to launch her new webpage on transformative, federally funded work happening right now at UW–Madison. You can read about the Gamm Lab’s research here and learn more about our university’s other impactful, cutting-edge research projects by visiting the Chancellor’s webpage here.
In a new study published in Stem Cell Reports, the Gamm Lab partnered with researchers at the Morgridge Institute for Research to develop lab-grown pig retinal organoids. They found that pig-derived photoreceptors shared many similarities with those made from human retinal organoids. The researchers have now begun to do transplants in pigs using photoreceptors from the …